In a randomized, double-blind, placebo-controlled trial assessing oligo-fucoidan’s role in asthma patients, it lowered serum IL-1b and IL-6 after 4 weeks and significantly reduced serum IL-8 after 24 weeks [49]. Here, CXCL8 is linked to asthma.